Last reviewed · How we verify
NCT03781492: PRESAGE
Stable Angina Management and Treatment
trial in Stable Angina in 25,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Silesian Centre for Heart Diseases |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 25,000 |
| Start date | 1 January 2006 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Poland |
Conditions studied
- Stable Angina — all drugs for Stable Angina →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Silesian Centre for Heart Diseases — full company profile →
Who can join
18 and older, any sex, with Stable Angina or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Prospective REgistry of Stable Angina manaGEment and Treatment (PRESAGE) is an observational study on an all-comer stable angina population hospitalised in a highly specialized cardiovascular centre with cardiac surgery facilities. The aim of the study is to assess the clinical characteristics, treatment modalities, early and long-term outcomes in this population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A comparison of the management and five-year outcomes of patients treated for chronic coronary syndrome between 2006-2007 and 2015-2016 - insights from the PRESAGE registry.
Kozłowska-Karaca I, Desperak P, Gąsior M, Trzeciak P. · · 2024 · PMID 39445889 · DOI 10.5603/cj.100464
Verify or expand the search:
- PubMed search for NCT03781492
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stable Angina
Currently open trials in the same condition.
- NCT06436092 — Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry) · recruiting
- NCT05972070 — Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence · recruiting
- NCT05865600 — Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome · NA · recruiting
- NCT05230446 — PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlus · NA · recruiting
- NCT05255705 — Barts Revascularisation Registry · recruiting
Other Silesian Centre for Heart Diseases trials
Trials by the same sponsor.
- NCT04453748 — The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications · unknown
- NCT04450745 — Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients · NA · completed
- NCT03588962 — Metal Allergy In-Stent Restenosis Study · NA · unknown
- NCT03654859 — Silesian Registry of Out-of-Hospital Cardiac Arrests · unknown
- NCT03065543 — Hyperlipidemia Therapy TERCET Zabrze Registry · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03781492 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Silesian Centre for Heart Diseases
- Last refreshed: 26 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03781492.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing